Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00704379 · ClinicalTrials.gov registry record · Phase 2
Treatment Strategy to Prevent Mood Disorders Following Traumatic Brain Injury
A Phase 2 study of Traumatic Brain Injury, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 94
- Enrollment target
- 1
- Study location
NCT00704379 is a Phase 2 study of Traumatic Brain Injury that has completed, run by Baylor College of Medicine. The registered enrollment target is 94 participants, below the 277-participant average among 171 other Traumatic Brain Injury trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00704379, a Phase 2 study of Traumatic Brain Injury, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 94 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine the efficacy of sertraline to prevent the onset of mood and anxiety disorders during the first six months after traumatic brain injury.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Sertraline
Study Locations (1)
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2008-06 |
| Est. Completion | 2014-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00704379
The ClinicalTrials.gov registry entry for NCT00704379 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 277-participant average among 171 other Traumatic Brain Injury trials with a reported enrollment target (66% lower). The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Traumatic Brain Injury appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00704379 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00704379 about?
NCT00704379 is a clinical study titled "Treatment Strategy to Prevent Mood Disorders Following Traumatic Brain Injury". The purpose of this study is to examine the efficacy of sertraline to prevent the onset of mood and anxiety disorders during the first six months after traumatic brain injury.
What is the current status of trial NCT00704379?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 94 participants. The study started on 2008-06. Estimated completion is 2014-04.
What conditions does trial NCT00704379 study?
This clinical trial studies the following conditions: Traumatic Brain Injury.
What interventions are being tested in trial NCT00704379?
The interventions under investigation include: Placebo (DRUG), Sertraline (DRUG).
Who is sponsoring clinical trial NCT00704379?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00704379 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Traumatic Brain Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Improving Neurotrauma by Depolarization Inhibition With Combination Therapy (INDICT)
RECRUITING · Phase 2
-
Understanding and Treating Traumatic Brain Injury (TBI) Associated Photophobia With Botulinum Toxin Type A (BoNT-A)
RECRUITING · Phase 2
-
Hyperbaric Oxygen Brain Injury Treatment Trial
RECRUITING · Phase 2
-
High Intensity Step Training After Traumatic Brain Injury
RECRUITING · Phase 2
-
Sildenafil for Microvasculopathy in Chronic TBI
RECRUITING · Phase 2
-
Cannabidiol as a Treatment for PTSD and PTSD Comorbid With TBI
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.